Switch strategies in 2014

por Podzamczer, Daniel
Publicado 2014

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

por Saumoy, Maria, Sanchez-Quesada, Jose Luís, Ordoñez-Llanos, Jordi, Podzamczer, Daniel
Publicado 2021

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily

por Tiraboschi, Juan, Imaz, Arkaitz, Ferrer, Elena, Saumoy, Maria, Rozas, Nerea, Maso, Marga, Vila, Antonia, Niubo, Jordi, Podzamczer, Daniel
Publicado 2014

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice

por Ferrer, Elena, Navarro, Antonio, Curto, Jordi, Medina, Pilar, Rozas, Nerea, Barrera, Gladys, Saumoy, Maria, Manuel Tiraboschi, Juan, Gomez, Carmen, Podzamczer, Daniel
Publicado 2014

Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional study

por Imaz, Arkaitz, Camoez, Mariana, Di Yacovo, Silvana, Gasch, Oriol, Dominguez, M Angeles, Vila, Antonia, Maso-Serra, Margarita, Pujol, Miquel, Podzamczer, Daniel
Publicado 2015

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI

por Di Yacovo, Silvana, Molto, Jose, Ferrer, Elena, Curran, Adrian, Jayne Else, Laura, Clotet, Bonaventura, Tiraboschi, Juan, Niubo, Jordi, Vila, Antonia, Podzamczer, Daniel
Publicado 2014

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

por Ramón Santos, José, Saumoy, María, Curran, Adrian, Bravo, Isabel, Navarro, Jordi, Estany, Carla, Podzamczer, Daniel, Ribera, Esteban, Negredo, Eugenia, Clotet, Bonaventura, Paredes, Roger
Publicado 2014

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004–2018

por Domínguez-Domínguez, Lourdes, Rava, Marta, Bisbal, Otilia, Lopez-Cortés, Luis, Portilla, Joaquín, Podzamczer, Daniel, Olalla, Julián, Fuster, Daniel, Rubio, Rafael, Jarrín, Inmaculada, Iribarren, José Antonio, Moreno, Santiago
Publicado 2022

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation

por Rosado-Sánchez, Isaac, Herrero-Fernández, Inés, Genebat, Miguel, Del Romero, Jorge, Riera, Melchor, Podzamczer, Daniel, Olalla, Julián, Vidal, Francesc, Muñoz-Fernández, Mª Angeles, Leal, Manuel, Pacheco, Yolanda M.
Publicado 2018

Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability

por Torres, Montserrat, Silva-Klug, Ana, Ferrer, Elena, Saumoy, Maria, Trenti, Loris, Tous, Sara, Esteban, Ana, Baixeras, Nuria, Catala, Isabel, Vidal, August, G Bravo, Ignacio, Podzamczer, Daniel, de Sanjose, Silvia
Publicado 2023

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-...

por Di Yacovo, Silvana, Saumoy, Maria, Sánchez-Quesada, José Luís, Navarro, Antonio, Sviridov, Dmitri, Javaloyas, Manuel, Vila, Ramon, Vernet, Anton, Low, Hann, Peñafiel, Judith, García, Benito, Ordoñez-Llanos, Jordi, Podzamczer, Daniel
Publicado 2020

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

por Rockstroh, Jürgen K., Asmuth, David, Pantaleo, Giuseppe, Clotet, Bonaventura, Podzamczer, Daniel, van Lunzen, Jan, Arastéh, Keikawus, Mitsuyasu, Ronald, Peters, Barry, Silvia, Nozza, Jolliffe, Darren, Ökvist, Mats, Krogsgaard, Kim, Sommerfelt, Maja A.
Publicado 2019

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

por Wang, Ruolan, Wright, Jonathan, Saggu, Parminder, Ait-Khaled, Mounir, Moodley, Riya, Parry, Chris M., Lutz, Thomas, Podzamczer, Daniel, Moore, Richard, Górgolas Hernández-Mora, Miguel, Kinder, Clifford, Wynne, Brian, van Wyk, Jean, Underwood, Mark
Publicado 2023

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Rand...

por Walmsley, Sharon, Baumgarten, Axel, Berenguer, Juan, Felizarta, Franco, Florence, Eric, Khuong-Josses, Marie-Aude, Kilby, J. Michael, Lutz, Thomas, Podzamczer, Daniel, Portilla, Joaquin, Roth, Norman, Wong, Deborah, Granier, Catherine, Wynne, Brian, Pappa, Keith
Publicado 2015

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients

por Podzamczer, Daniel, Fredy Rojas, Jhon, Neves, Isabel, Ferrer, Elena, Llibre, Josep M, Leal, Manuel, Gorgolas, Miguel, Jose, Crusells M, Gatell, Josep M, Correia Abreu, Ricardo, Curto, Jordi, Domingo, Pere, Pilar, Barrufet M, Rozas, Nerea
Publicado 2014

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

por Smith, Graham, Henry, Keith, Podzamczer, Daniel, Masiá, Mar, Bettacchi, Christopher, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Sutton, Kenneth, Zhang, Feifan, McCoig, Cynthia C, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Spreen, William, Margolis, David
Publicado 2020

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study

por Podzamczer, Daniel, Rozas, Nerea, Domingo, Pere, Ocampo, Antonio, Van den Eynde, Eva, Deig, Elisabeth, Vergara, Antonio, Knobel, Hernando, Pasquau, Juan, Antela, Antonio, Crespo, Manuel, Clotet, Bonaventure, Muñoz, Jessica, Fernandez, Pedro, Geijo, Paloma, Rodríguez de Castro, Eduardo, Diz, Julio, Casado, Araceli, Torres, Covadonga
Publicado 2014

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

por Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz
Publicado 2016

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

por Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz
Publicado 2017

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

por Gonzalez-Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz-Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, Martinez-Picado, Javier, Cerezuela, Pablo, Soria, Ainara, Marquez-Rodas, Ivan, Mandala, Mario, Berrocal, Alfonso
Publicado 2021